Hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement. Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA.
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy / S.K. Khaled, K. Claes, Y.T. Goh, Y.L. Kwong, N. Leung, W. Mendrek, R. Nakamura, J. Sathar, E. Ng, N. Nangia, S. Whitaker, A. Rambaldi. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - (2022). [Epub ahead of print] [10.1200/JCO.21.02389]
Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy
A. Rambaldi
Ultimo
2022
Abstract
Hematopoietic stem-cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a serious complication with significant mortality and no approved therapy. HSCT-TMA results from endothelial injury, which activates the lectin pathway of complement. Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jco.21.02389.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
474.06 kB
Formato
Adobe PDF
|
474.06 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
